Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1521188

Protective Effect of Resveratrol on Retinal Damage in Glaucoma: A Systematic Review and Meta-Analysis of Preclinical Studies

Provisionally accepted
Feng Zhang Feng Zhang 1Tao Li Tao Li 2*Junli Wan Junli Wan 1*Lu Wang Lu Wang 1*Wenmei Guo Wenmei Guo 1*Yue Hu Yue Hu 1*Hao Wang Hao Wang 1*Wei Bian Wei Bian 1*
  • 1 Army Medical University, Chongqing, China
  • 2 Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Resveratrol, a polyphenolic compound commonly found in natural plants and fruits, exhibits potential in preventing optic nerve damage in glaucoma, as indicated by several animal studies. However, there is presently a dearth of relevant evidence available for comprehensive summarization. In this study, we conducted an extensive search across 7 electronic databases, encompassing all pertinent animal studies for a systematic review and meta-analysis. Methodological quality was evaluated using SYRCLE's bias risk tool, with statistical analysis performed using Stata 17.0. The primary outcome measures included the survival of retinal ganglion cells and retinal thickness. The comprehensive analysis of the 30 included studies revealed that resveratrol can enhance the expression of Sirtuin 1(SIRT1) protein in retinal tissue (SMD: 3.00, 95% CI: 2.46, 3.53, P=0.095), boost the survival rate of retinal ganglion cells (SMD: 4.33, 95% CI: 3.28, 5.38, P<0.05), decelerate the thinning of retinal thickness (SMD: 4.26, 95% CI: 2.77, 5.75, P<0.05), and enhance visual function. Its potential mechanism of action may involve the suppression of pro-inflammatory cytokine levels and cell apoptosis. Resveratrol emerges as a promising agent for mitigating glaucoma-related retinal damage. However, given that the animal research models utilized in the study may not fully reflect the intricate scenarios of multiple coexisting diseases in clinical settings, and the administration methods in animal models may differ from those in clinical practice, future studies should aim to provide higher levels of evidence to facilitate the clinical translation of these findings.

    Keywords: resveratrol, Glaucoma, Retina, preclinical studies, systematic review and meta-analysis

    Received: 01 Nov 2024; Accepted: 26 Dec 2024.

    Copyright: © 2024 Zhang, Li, Wan, Wang, Guo, Hu, Wang and Bian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Tao Li, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, Sichuan Province, China
    Junli Wan, Army Medical University, Chongqing, China
    Lu Wang, Army Medical University, Chongqing, China
    Wenmei Guo, Army Medical University, Chongqing, China
    Yue Hu, Army Medical University, Chongqing, China
    Hao Wang, Army Medical University, Chongqing, China
    Wei Bian, Army Medical University, Chongqing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.